GlassScriptPhysician profile
Mark K Banno
NPI 1669600219
$10,344.89
in general payments reported to CMS, 2019-2025
33 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $616 · 2021: $1,609 · 2022: $872 · 2023: $1,137 · 2024: $2,303 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,538.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,774.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,472.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,200.06 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $960.52 | 2019-2025 | |
| Lilly USA, LLC | $744.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.91 | 2019-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $430.16 | 2019-2022 | |
| Exact Sciences Corporation | $428.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $419.92 | 2021-2025 | |
| Madrigal Pharmaceuticals | $355.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $310.90 | 2021-2023 | |
| Glaxosmithkline, LLC. | $275.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $231.30 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $178.39 | 2024-2025 | Voquezna |
| Horizon Therapeutics Plc | $142.78 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $124.62 | 2020-2021 | |
| Kerecis Limited | $124.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| E.R. Squibb & Sons, L.L.C. | $85.68 | 2022-2025 | Eliquis |
| Boston Scientific Corporation | $70.08 | 2021-2025 | General - Pain Management |
| Shield Therapeutics INC | $68.01 | 2022-2023 | Accrufer |
| Allergan, INC. | $58.75 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $45.46 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $42.50 | 2019-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.02 | 2024 | Caplyta |
| Abbott Laboratories | $34.41 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $33.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.30 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $29.37 | 2022 | |
| Sumitomo Pharma America, INC. | $28.85 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $26.27 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $21.70 | 2024 | |
| Phadia US INC. | $19.81 | 2021 | |
| Ascend Therapeutics US, LLC | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Banno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.